4th International HIV/Viral Hepatitis Co-Infection Meeting
The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
22-23 July 2017, Paris, France


  • Overview
  • Organizing Committee
  • Partners
  • Programme
  • Poster Abstracts

The 4th International HIV/Viral Hepatitis Co-Infection Meeting is organized by the International AIDS Society (IAS) and will take place prior to the 9th IAS Conference on HIV Science (IAS 2017) at the Campus des Cordeliers, Université Pierre et Marie-Curie (UPMC) in Paris, France.

Building on the previous three successful annual meetings, the 4th International HIV/Viral Hepatitis Co-Infection Meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV. While the focus of the 3rd International HIV/Viral Hepatitis Co-Infection Meeting was on medical and access challenges in low- and middle-income settings in particular, the 4th meeting will also take advantage of the meeting location to explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia. It will also be an opportunity to take stock of some of the scientific breakthroughs and brainstorm on concrete actions to support the WHO targets in their sector strategies.

The meeting will focus on addressing the challenges of achieving elimination of hepatitis B and C in HIV-infected populations worldwide through reviewing the latest information on epidemiology, prevention, diagnostics and treatment. Furthermore, the meeting will have a particular focus on access to care and new curative treatments especially for key populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men. These topics will be explored through a combination of keynote presentations to provide broad and assertive overviews of the different areas, invited and abstract-based oral and poster presentations to highlight cutting-edge science, and invited panel discussions and debates, with strong community participation, to go beyond the data and address the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.

Co-Chairs

Name
Organization
City
Marina Klein
McGill University and CIHR Canadian HIV Trials Network
Montreal, Canada
Karine Lacombe
Hôpital Saint-Antoine
Paris, France

Members

Name
Organization
City
Monique Andersson
Stellenbosch University, Faculty of Health Sciences
Cape Town, South Africa
Isabelle Andrieux-Meyer
Drugs for Neglected Diseases initiative
Geneva, Switzerland
Sanjay Bhagani
Royal Free Hospital
London, UK
Christoph Boesecke
University of Bonn
Bonn, Germany
Laurent Castera
Hôpital Beaujon
Paris, France
Greg Dore
Kirby Institute
Sydney, Australia
Jordan Feld
University of Toronto
Toronto, Canada
Niklas Luhmann
Médecins du Monde
Paris, France
Ludmila Maistat
Alliance for Public Health
Kiev, Ukraine
Gail Matthews
Kirby Institute
Sydney, Australia
Sébastien Morin
International AIDS Society
Geneva, Switzerland
Jacques Normand
National Institute on Drug Abuse
Washington D.C., USA
Jean-Michel Pawlotsky
Henri Mondor University Hospital
Créteil, France
Marion Peters
University of California
San Francisco, USA
Lionel Piroth
CHU Dijon Bourgogne
Dijon, France
Jürgen Rockstroh
University of Bonn
Bonn, Germany
Tracy Swan
Médecins Sans Frontières
New York, USA

See the programme here

All meeting attendees (including media representatives) agree to abide by the IAS 2017 embargo policy for abstract-based presentations (in particular posters)

All meeting attendees (including media representatives) agree to abide by the IAS 2017 embargo policy for abstract-based presentations (in particular posters)

Epidemiology

Abstract title
Abstract authors
Assessment of Prevalence of HIV, Hepatitis C, HIV/Hepatitis C co-infection and risk behaviours among Female Injecting Drug Users in Nepal
J. Damas, K. Deuba, U. Shrestha, B. Rawal, T. Paudel, G. Marrone
Burden of infectious diseases and substance abuse among incarcerated women in Kuala Lumpur, Malaysia
V. Pillai, C. Pedersen, J. Wickersham, F. Altice, A. Kamarulzaman
Chronic hepatitis C and HIV co-infection among people who inject drugs along the Kenyan Coast
R.N. Shah, J. Kinyua, A. Kattammaiyo, K. Mandaliya, B. Langat, S. Bhagani, M. Thursz, E. Songok, M. Lemoine
Countrywide epidemiology of B, C and Delta hepatitis in Burkina Faso: the ANRS 12270 clustered cross-sectional study
N. Meda, E. Tuaillon, D. Kania, A. Kiendrebeogo, A. Pisoni, S. Zida, K. Bollore, I. Meda, D. Laureillard, J.P. Moles, N. Nagot, Y. Nebie, P. Vande Perre, P.F. Dujols
HCV genotype profile in Brazil among HIV infected and uninfected individuals: a survey truly representative of an entire country
M. Nutini, J. Hunter, A.F. Pires, I. Kohiyama, M. Camargo, M.C. Sucupira, D. Ricardo
Hepatitis E virus serological and molecular testing in 1979 patients followed-up in 2014-2016 in HIV reference centers of university hospitals of Marseille, southeastern France
P. Colson, C. Dhiver, H. Tissot-Dupont, S. Mokhtari, A. Motte, I. Ravaux, C. Toméi, C. Tamalet, S. Aherfi, P. Brouqui, A. Stein, A. Menard
Predictors and incidence of sexually transmitted Hepatitis C virus infection in HIV positive men who have sex with men
N.A. Medland, C. Eric P F, C.S. Bradshaw, T.H.R. Read, J.J. Sasadeuz, C.K. Fairley
Predictors of HCV Seroconversion in People Who Inject Drugs in 5 Regions of Ukraine
A. Meteliuk, A. Mazhnaya, S. Filippovych, F.L. Altice
Prevalence and risk factors associated with HIV/viral hepatitis B and C co-infections among People Who Inject Drugs in Mozambique, 2013-2014
C.A. Semá Baltazar, M. Boothe, I. Sathane, E. Fazito, R. Horth, N. Bhatt
Recent incarceration and risk of hepatitis C and HIV transmission amongst people who inject drugs: A systematic review and meta-analysis
J. Stone, M. Hickman, A. Lim, H. Fraser, J. Walker, L. MacGregor, A. Trickey, S. Abbott, Z. Ward, N.K. Martin, P. Vickerman
Trends in Cause-Specific Mortality in HIV-hepatitis C (HCV) Co-infected Patients in Canada (2003 - 2016): Early Impact of HCV Therapy
N. Kronfli, S.R. Bhatnagar, M. Hull, E. Moodie, C. Cooper, N. Pick, S. Walmsley, M.-L. Vachon, V. Martel-Leferriere, J. Gill, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators

Immunology

Abstract title
Abstract authors
Circulating Mucosal associated invariant T cells (MAITs) fail to be recovered by successful direct-acting antiviral therapy (DAA) in HIV/HCV co-infected patients
E.S. Cannizzo, M. Cerrone, E. Merlini, B. van Wilgenburg, L. Swadling, C. Tincati, A. De Bona, A. d'Arminio Monforte, P. Klenerman, G. Marchetti
Untreated HCV-coinfection in HIV-infected patients induces additional CD4+ T-lymphocyte deficiency due to mobilization of naive cells into immune response resulting in their regeneration failure
K. Shmagel, E. Saidakova, L. Korolevskaya, N. Shmagel, V. Chereshnev

Diagnostics

Abstract title
Abstract authors
Chronic hepatitis C among intravenous drug users in Tanzania: assessment of the liver disease and utility of HCV core antigen detection and quantification
Z. Mohamed, J. Mbwambo, Y. Shimakawa, L. Poiteau, S. Chevaliez, J.-M. Pawlotsky, J. Rwegasha, S. Bhagani, S. Taylor-Robinson, J. Makani, M. Thursz, M. Lemoine
Comparison of two Immunoassays for Simultaneous Detection of HCV Antigen and Antibodies among HCV/HIV Co-infected Patients in Dried Serum Spots
A. Eshetu, B. Bartmeyer, V. Bremer, D. Schmidt, C.-T. Bock, N. Bannert, A. Hauser
Usual APRI score thresholds lack sensitivity to prioritize for Hepatitis C treatment in a HCV/HIV coinfected cohort in Cambodia
A. De Weggheleire, S. An, J. Buyze, S. Thai, S. Francque, L. Lynen

Linkage to care

Abstract title
Abstract authors
Hepatitis C care cascade for people living with HIV in the country of Georgia
N. Chkhartishvili, A. Abutidze, N. Bolokadze, O. Chokoshvili, N. Dvali, L. Sharvadze, T. Tsertsvadze
Integrated Surveillance for HIV, Syphilis, HBV & HCV in pregnant women attending ANC Sentinel Surveillance Sites in Eritrea, 2016
A.B. Mesfin, H. Ahmed, M. Asrat, T. Asfaha, N. Tesfamichael

Treatment

Abstract title
Abstract authors
Alanine aminotransferase level monitoring to detection hepatitis B virus reactivation in 170 HIV/hepatitis C virus-infected patients on direct-acting agent-based therapies
P. Colson, S. Mokhtari, H. Tissot-Dupont, C. Dhiver, I. Ravaux, L. Meddeb, A. Motte, C. Tamalet, S. Aherfi, P. Brouqui, A. Stein, A. Menard
Association of uncontrolled HIV-RNA with failure to direct acting antiviral (DAA) combinations in HIV/HCV co-infected patients on antiretroviral therapy (ART) - ANRS CO13 HEPAVIH cohort
D. Salmon, C. Gilbert, J. Chas, L. Piroth, K. Lacombe, C. Katlama, P. Trimoulet, C. Solas, G. Peytavin, H. Aumaitre, L. Alric, F. Boué, P. Morlat, I. Poizot-Martin, E. Billaud, E. Rosenthal, A. Naqvi, P. Miailhes, L. Esterle, P. Carrieri, P. Sogni, F. Dabis, L. Wittkop, HEPAVIH ANRS CO13 Study Group
Chronic Hepatitis C in Human Immunodeficiency Virus infected patients: real-life treatment with new generation Direct-Acting Antivirals in a Portuguese centre
A. Silva-Pinto, R. Ruas, I. Abreu, F. Ceia, A.C. Carvalho, N. Neves, A.S. Santos, J. Soares, C. Piñeiro, R. Serrão, A. Sarmento
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPoster exhibitionDITION-2 Study
J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D. Wyles, A. Luetkemeyer, R. Soto-Malave, R. Flisiak, S. Bhagani, K. Sherman, P. Ruane, J. Sasadeusz, J. Slim, Z. Zhang, T. Ng, R. Trinh, M. Sulkowski
HCV Cure for HIV-infected patients: Not so easy to achieve in routine practice
H. Laroche, C. Lions, C. Solas, P. Carrieri, O. Faucher-Zaegel, S. Bregigeon, C. Tamalet, E. Ressiot, V. Obry-Roguet, B. Canet, I. Poizot-Martin
Role of PLHIV networks in facilitating Hepatitis C cascade of care in South and South East Asia
O. Syarif
The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries
A. Hill, S. Nath, B. Simmons

Outcomes and co-morbidities

Abstract title
Abstract authors
Causes of death in HIV-monoinfected and HIV/HCV-coinfected patients in Brazil, 2000-2014
M.E. Santos, R. Abrahão Ribeiro, A. Stevens, M.P. Carrieri, W. Navegantes de Araújo
Comparative Steatosis Rates by Liver Biopsy and Transient Elastography Controlled Attenuated Parameter (CAP) in Hepatitis C (HCV) and HIV/HCV Coinfection in a Large U.S. Hepatitis Clinic: Time to Take Notice
J. Martin, O. Adeyemi, K. Burke, I. Alvaraz, C. Winston, S. Markham, B. Go, G. Huhn
Coffee intake modifies the relationship between alcohol consumption and liver fibrosis in patients co-infected with HIV and hepatitis C virus (ANRS CO13-HEPAVIH cohort)
M.E. Santos, S. Rosellini, F. Marcellin, C. Protopopescu, L. Wittkop, L. Esterle, P. Morlat, D. Zucman, A. Gervais, B. Spire, F. Dabis, D. Salmon-Ceron, M.P. Carrieri, ANRS CO13-HEPAVIH Cohort Study Group
Daily cannabis use and reduced risk of severe steatosis in a population of patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH)
S.E. Nordmann, A. VIlotitch, P. Roux, L. Esterle, B. Spire, F. Marcellin, D. Salmon-Ceron, F. Dabis, J. Chas, D. Rey, L. Wittkop, P. Sogni, P. Carrieri, ANRS CO13 HEPAVIH study group
Does the Non-Alcoholic Fatty Liver Disease (NAFLD) Score Predict Liver Fibrosis Progression after Hepatitis C Virus (HCV) Treatment in Human Immunodeficiency Virus (HIV)-HCV Co-infected Patients?
N. Kronfli, R. Nitulescu, S. Walmsley, C. Cooper, S. Haider, J. Gill, M.-L. Vachon, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators
Increased risk of overweightness and obesity after HCV clearance in patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH cohort)
I. Yaya, C. Protopopescu, F. Marcellin, L. Wittkop, L. Esterle, D. Salmon-Céron, I. Poizot-Martin, E. Rosenthal, F. Bani-Sadr, S. Nordmann, M.P. Carrieri, The ANRS CO13-HEPAVIH Study Group
Occult liver cirrhosis diagnosed by transient elastography is frequent and under-monitored in HIV-infected patients: results of a large-scale screening program
A. Benmassaoud, T. Pembroke, B. Lebouche, P. Ghali, M. Deschenes, M. Klein, G. Sebastiani
Sustained virologic response (SVR) after hepatitis C virus (HCV) treatment does not lead to improved renal function in HIV/HCV coinfected patients
C. Rossi, E. Moodie, M. Hull, V. Martel-Lafferriere, M.-L. Vachon, C. Cooper, N. Pick, S. Walmsley, M. Klein, Canadian Coinfection Cohort

Scale-up

Abstract title
Abstract authors
An economic evaluation of the integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis
L. Zhang, N. Ishikawa, J.V. Woodring, Y. Tao, M. Nagai, Y.-R. Lo
Eliminating HCV/HIV coinfection through enhanced treatment: HCV treatment in primary care is feasible and highly effective
A.L. Bowring, J.S. Doyle, J. Roney, D. Iser, J. Sasadeusz, M. O'Reilly, C. Fairley, E. Gane, H. Jennifer, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.-K. Tee, M. Hellard E
Expanding the Provider Base: HIV and Hepatitis C Clinical Preceptorships in New York State
N. Harris, T. Wilder, J. Steinke, R. Walsh, A. Urbina
Generic treatments for HIV, HBV, HCV, TB could be mass produced for < $90 per patient
A. Hill, M. Barber, D. Gotham, J. Fortunak, A. Pozniak

HBV

Abstract title
Abstract authors
HBV co-infection is associated with high one-year mortality in HIV-infected Tanzanians on ART
B. Christian, E. Fabian, L.R. Ammerman, I. Macha, C. Gawile, S. Mpangala, N. Ulenga, C. Thio, R. Murphy, C. Hawkins
Hepatitis B Virus Infection in HIV-1 Negative and Positive Pregnant Women in Botswana, Implications for HBV Vertical Transmission
T. Mbangiwa, M. Anderson, A. Needleman, P.K. Thami, M. Leteane, S. Moyo, D. Setlhare, G. Mayondi, T. Sebunya, T.W. Choga, R. Musonda, M. Essex, S. Lockman, S. Gaseitsiwe
Preliminary results of prevention of mother-to-child transmission of hepatitis B virus through treatment of mothers and vaccination of newborns at Ouagadougou, Burkina Faso
A.N. Guingane, N. Meda, R. Sombié, I. Guiraud, A. Bougouma